The Latest Breaking News from FDA

Kisunla manufactured by Eli Lilly could significantly slow cognitive decline in people with early symptomatic Alzheimer's disease, according to results of the company's clinical trials.

FDA recalls potassium chloride capsules from Glenmark Pharmaceuticals and American Health Packaging due to failed dissolution, posing heart attack risks.

FDA approves Eli Lilly's donanemab for early Alzheimer's, offering hope for patients and caregivers. Treatment priced at 5 per vial.

Salmonella can cause symptoms that begin six hours to six days after ingesting the bacteria

At least 48 people in 24 states said they got sick after eating Diamond Shruumz-brand products

Eli Lilly says Kisunla demonstrated ‘meaningful results’ for people showing early symptoms of the disease

Eli Lilly won FDA approval for its Alzheimer's treatment, donanemab, on Tuesday. But Eli Lilly stock remained in the red.

U.S. health officials have approved a new Alzheimer’s drug that can modestly slow the disease

The blend of growth potential and stability in mid-cap pharma stocks is driven by rising demand for innovative therapies, strong economic conditions, and technological advancements that boost the sector's growth trajectory. Therefore, considering strong mid-cap stocks like Amphastar Pharmaceuticals (AMPH), Catalyst Pharmaceuticals (CPRX), and ACADIA Pharmaceuticals (ACAD), expected to soar…

 The decision comes weeks after the FDA authorized the marketing of the first menthol-flavored vaping products.

The Supreme Court announced Tuesday it will decide disputes over online access to pornography in Texas and FDA approval of vapes.